Conclusion of non-exclusive discount agreements for medicines containing brinzolamide and timolol under an open-house model

Summary

The procurement concerns non-exclusive discount agreements for medicines containing the active ingredients brinzolamide and timolol, concluded under an open-house model. Pharmaceutical companies that meet the participation conditions may enter into agreements, which do not grant exclusive supply rights. Actual demand and purchase volumes are not known in advance, and no minimum purchase volume is guaranteed. The agreements will end no later than 31 December 2028.